Lixisenatide is safe and effective for controlling HbA1c and reducing weight and 2-hour postprandial plasma glucose in older adults with type 2 diabetes inadequately controlled with their current ...

Lixisenatide (trade name: Lyxumia) has been approved in Germany since February 2013 for the treatment of type 2 diabetes mellitus in combination with oral blood-glucose lowering drugs or basal ...

Sanofi said it will resubmit lixisenatide, its once-daily treatment for type 2 diabetes patients, to the FDA in the third quarter. The drugmaker announced its plans to resubmit the GLP-1 receptor ...

Lixisenatide was in-licensed from Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL), www.zealandpharma.com, and was approved in Europe in 2013 for the treatment of adults with type 2 diabetes ...

Lixisenatide (trade name: Lyxumia) has been approved in Germany since February 2013 for the treatment of type 2 diabetes mellitus in combination with oral blood-glucose lowering drugs or basal ...

Patients were randomized to lixisenatide two-step titration (10mcg for 1 week, 15mcg for 1 week then 20mcg; n=120); lixisenatide one-step titration (10mcg for 2 weeks then 20mcg; n=119) or placebo ...

(HealthDay News) — Lixisenatide is more effective than placebo for older patients with uncontrolled diabetes on their current medication, with no unexpected safety findings, according to a study ...

Sanofi intends to resubmit the NDA for lixisenatide in 2015, post completion of the ELIXA CV study. The U.S. Food and Drug Administration (:FDA) had accepted the lixisenatide NDA in February this ...

Lixisenatide, approved in Europe under the brand name Lyxumia, treats adults with type 2 diabetes has been studied both alone and in combination with Sanofi’s mainstay insulin, Lantus.

PARIS, France, June 9, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today data demonstrating Lyxumia®* (lixisenatide), a once-daily investigational GLP-1 agonist, in ...

PARIS -- Sanofi announced today the presentation of full results of the Phase IIIb ELIXA study, which was designed to assess the cardiovascular (CV) safety of Lyxumia® (lixisenatide) in adults ...